We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DAVE:NASDAQDave Inc. Analysis

Data as of 2026-03-28 - not real-time

$174.95

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Dave Inc. is trading at $174.95, just above its calculated support of $173.06 and well below its 20‑day SMA of $207.60, indicating a price that is still anchored to a technical floor. The RSI of 34.5 suggests the stock is oversold, while a bearish MACD histogram reinforces short‑term downside pressure. However, the company’s fundamentals are compelling: revenue surged 62% year‑over‑year to $554 M, gross margins sit at an impressive 70%, and operating margins are near 40%, delivering a profit margin of 35% and an ROE above 70%. Valuation is mixed – the forward PE of 9.98 is well under the industry average of 32, yet the DCF‑derived fair value of $73.56 is far below the current price, flagging the stock as potentially overvalued on a cash‑flow basis. Recent material news adds momentum: the firm announced a $150 M capital raise, a $175 M convertible‑note issuance earmarked for a $70.5 M share repurchase, and an AI‑driven credit platform slated to boost 2026 revenue to $690‑$710 M.
Overall, the blend of strong growth metrics, a “strong buy” analyst consensus, and a high‑beta, high‑volatility profile suggests a cautious but opportunistic stance. The stock’s lack of dividend payout underscores reliance on reinvested earnings for value creation. Investors should weigh the upside from the AI‑driven expansion against the downside risk implied by technical weakness and elevated beta.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI indicates oversold conditions near support
  • Bearish MACD histogram suggests continued short‑term weakness
  • Decreasing volume adds uncertainty to price moves

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 62% and expanding AI‑driven credit platform
  • Strong operating margins and high ROE supporting earnings momentum
  • Analyst consensus of "strong buy" with a median target of $318

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic capital raise and convertible‑note repurchase strengthen balance sheet
  • Projected 2026 revenue of $690‑$710 M indicates sustained growth trajectory
  • High beta and volatility are offset by robust cash generation and reinvestment

Key Metrics & Analysis

Financial Health

Revenue Growth62.40%
Profit Margin35.34%
P/E Ratio12.9
ROE73.11%
ROA30.37%
Debt/Equity21.32
P/B Ratio6.7
Op. Cash Flow$290.0M
Free Cash Flow$25.5M
Industry P/E32.0

Technical Analysis

TrendNeutral
RSI34.5
Support$173.06
Resistance$227.69
MA 20$207.60
MA 50$189.86
MA 200$210.15
MACDBearish
VolumeDecreasing
Fear & Greed Index65.98

Valuation

Fair Value$73.56
Target Price$318.00
Upside/Downside81.77%
GradeOvervalued
TypeBlend

Risk Assessment

Beta2.01
Volatility64.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.